Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2016

Open Access 01-12-2016 | Research article

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey

Authors: Roberta Ramonda, Antonio Marchesoni, Antonio Carletto, Gerolamo Bianchi, Maurizio Cutolo, Gianfranco Ferraccioli, Enrico Fusaro, Salvatore De Vita, Mauro Galeazzi, Roberto Gerli, Marco Matucci-Cerinic, Giovanni Minisola, Carlomaurizio Montecucco, Raffaele Pellerito, Fausto Salaffi, Giuseppe Paolazzi, Piercarlo Sarzi-Puttini, Raffaele Scarpa, Gianfilippo Bagnato, Giovanni Triolo, Guido Valesini, Leonardo Punzi, Ignazio Olivieri, ATLANTIS study group

Published in: Arthritis Research & Therapy | Issue 1/2016

Login to get access

Abstract

Background

The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability and working life.

Methods

The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients (ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients.

Results

Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS) (39 %) and psoriatic arthritis (PsA) (36 %). Respondents were working full-time (45 %), part-time (8 %) or had retired (22 %); 15 % were unemployed (for reasons linked to the disease or for other reasons, students or housewives). Patients reported disability (39 %), were receiving disability benefits (34 %), were experiencing important limitations that were hindering their professional development/career (36 %) and some had to change/leave their job or lost it because of SpA (21 %). Employed respondents (n = 383) had worked on average 32.2 h in the last 7 days. More hours of work were lost over the last 7 days due to SpA (2.39 h vs 1.67 h). The indirect costs of the disease amounted to €106/week for patients reporting well-being/good physical conditions/improvement and €216/week for those reporting permanent impairment.

Conclusions

Most patients were in the midst of their productive years and were experiencing considerable difficulties in carrying out their job because of the disease: half of them reported disability and one third were experiencing important limitations in their career perspective.
Appendix
Available only for authorised users
Literature
1.
go back to reference Van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nature Rev Rheumatol. 2015;11:110–8.CrossRef Van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nature Rev Rheumatol. 2015;11:110–8.CrossRef
2.
go back to reference Rudwaleit M, van der Heijde D, Landewè E, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.CrossRefPubMed Rudwaleit M, van der Heijde D, Landewè E, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.CrossRefPubMed
3.
go back to reference Rudwaleit M, van der Heijde D, Landewè E, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:777–83.CrossRef Rudwaleit M, van der Heijde D, Landewè E, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:777–83.CrossRef
4.
go back to reference Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 2012;64:1415–22.CrossRef Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 2012;64:1415–22.CrossRef
5.
go back to reference Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis. Results from the German Spondyloarthritis Inception Cohort. Arthrits Rheum. 2009;60:717–27.CrossRef Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis. Results from the German Spondyloarthritis Inception Cohort. Arthrits Rheum. 2009;60:717–27.CrossRef
6.
go back to reference Wallis D, Haroon N, Ayearst R, Listing J, Märker-Hermann E, Zeidler H, et al. Ankylosing Spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct disease? J Rheumatol. 2013;40:2038–4.CrossRefPubMed Wallis D, Haroon N, Ayearst R, Listing J, Märker-Hermann E, Zeidler H, et al. Ankylosing Spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct disease? J Rheumatol. 2013;40:2038–4.CrossRefPubMed
7.
go back to reference Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis. 2013;72(2):162–4.CrossRefPubMed Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis. 2013;72(2):162–4.CrossRefPubMed
8.
go back to reference Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2014;44(5):556–62.CrossRefPubMed Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2014;44(5):556–62.CrossRefPubMed
9.
go back to reference Song IH, Sieper J, Rudwaleit M. Diagnosing early ankylosing spondylitis. Curr Rheumatol Rep. 2007;9:367–74.CrossRefPubMed Song IH, Sieper J, Rudwaleit M. Diagnosing early ankylosing spondylitis. Curr Rheumatol Rep. 2007;9:367–74.CrossRefPubMed
10.
go back to reference van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.CrossRefPubMed van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.CrossRefPubMed
11.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed
12.
go back to reference Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK. Impact of functional impairment in ankylosing, spondylitis: impairment, activity limitation and participation restriction. J Rheumatol. 2005;32:516–23.PubMed Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK. Impact of functional impairment in ankylosing, spondylitis: impairment, activity limitation and participation restriction. J Rheumatol. 2005;32:516–23.PubMed
13.
14.
go back to reference Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis. A literature review from a global health systems perspective. P T. 2010;53(12):680–9. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis. A literature review from a global health systems perspective. P T. 2010;53(12):680–9.
15.
go back to reference Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheum. 2006;2:546–53.CrossRef Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheum. 2006;2:546–53.CrossRef
16.
go back to reference Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology. 2012;51:275–83.CrossRefPubMed Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology. 2012;51:275–83.CrossRefPubMed
17.
go back to reference Haglund E, Bremander A, Bergman S, Jacobsson LT, Petersson IF. Work productivity in a population-based cohort of patients with spondyloarthritis. Rheumatology. 2013;52:1708–14.CrossRefPubMed Haglund E, Bremander A, Bergman S, Jacobsson LT, Petersson IF. Work productivity in a population-based cohort of patients with spondyloarthritis. Rheumatology. 2013;52:1708–14.CrossRefPubMed
18.
go back to reference Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology. 2010;49:812–9.CrossRefPubMed Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology. 2010;49:812–9.CrossRefPubMed
19.
go back to reference Boonen A, van der Heijde D, Landewè R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61:429–37.CrossRefPubMedPubMedCentral Boonen A, van der Heijde D, Landewè R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002;61:429–37.CrossRefPubMedPubMedCentral
20.
go back to reference Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2015 pii: annrheumdis-2015-208174. doi: 10.1136/annrheumdis-2015-208174. [Epub ahead of print]. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2015 pii: annrheumdis-2015-208174. doi: 10.​1136/​annrheumdis-2015-208174. [Epub ahead of print].
21.
go back to reference Sieper J, Rudwaleit M, Khan M, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20:401–17.CrossRefPubMed Sieper J, Rudwaleit M, Khan M, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20:401–17.CrossRefPubMed
22.
go back to reference Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis and treatment. World J Orthop. 2014;5:637–543.CrossRef Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis and treatment. World J Orthop. 2014;5:637–543.CrossRef
27.
go back to reference Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol. 2001;28:1056–62.PubMed Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol. 2001;28:1056–62.PubMed
28.
go back to reference Healey EL, Haywood KL, Jordan KP, Garratt A, Packham JC. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol. 2011;40:34–40.CrossRefPubMed Healey EL, Haywood KL, Jordan KP, Garratt A, Packham JC. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol. 2011;40:34–40.CrossRefPubMed
29.
go back to reference van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009;11:R124.CrossRefPubMedPubMedCentral van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009;11:R124.CrossRefPubMedPubMedCentral
30.
go back to reference Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol. 2010;37:385–92.CrossRefPubMed Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol. 2010;37:385–92.CrossRefPubMed
31.
go back to reference Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology. 2008;47:481–3.CrossRefPubMed Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology. 2008;47:481–3.CrossRefPubMed
32.
go back to reference Van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006;55:569–74.CrossRefPubMed Van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006;55:569–74.CrossRefPubMed
33.
go back to reference Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis. 2013;72:1675–9.CrossRefPubMed Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis. 2013;72:1675–9.CrossRefPubMed
34.
go back to reference Prince DS, McGuigan LE, McGirr EE. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis. 2014;17:165–72.CrossRefPubMed Prince DS, McGuigan LE, McGirr EE. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis. 2014;17:165–72.CrossRefPubMed
Metadata
Title
Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey
Authors
Roberta Ramonda
Antonio Marchesoni
Antonio Carletto
Gerolamo Bianchi
Maurizio Cutolo
Gianfranco Ferraccioli
Enrico Fusaro
Salvatore De Vita
Mauro Galeazzi
Roberto Gerli
Marco Matucci-Cerinic
Giovanni Minisola
Carlomaurizio Montecucco
Raffaele Pellerito
Fausto Salaffi
Giuseppe Paolazzi
Piercarlo Sarzi-Puttini
Raffaele Scarpa
Gianfilippo Bagnato
Giovanni Triolo
Guido Valesini
Leonardo Punzi
Ignazio Olivieri
ATLANTIS study group
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2016
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-016-0977-2

Other articles of this Issue 1/2016

Arthritis Research & Therapy 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine